|
|
| (139 intermediate revisions by 7 users not shown) |
| Line 1: |
Line 1: |
| == Antibiotics By Diagnosis<br/> ==
| | {{Antibiotics by diagnosis navigation}} |
|
| |
|
| {| align="left" border="1" cellpadding="2" cellspacing="0"
| | ==See Also== |
| |-
| | *[[Antibiotics (Main)]] |
| | '''Diagnosis'''<br/>
| | *[[Antibiotics by organism]] |
| | '''Commonly Used Antibiotic(s)'''<br/>
| |
| |-
| |
| | Meningitis<br/>
| |
| |
| |
| Vancomycin 750mg (15mg/kg) IV
| |
|
| |
|
| ''PLUS''
| | ==References== |
| | | <references/> |
| Ceftriaxone 2g (50mg/kg) IV
| | [[Category:ID]] [[Category:Pharmacology]] |
| | |
| ''ADD''
| |
| | |
| Ampicillin 2g (50mg/kg) IV ''if concern for Listeria''
| |
| | |
| |-
| |
| | Otitis media<br/>
| |
| |
| |
| Amoxicillin 500mg (45mg/kg) PO Q12
| |
| | |
| ''OR''
| |
| | |
| Augmentin 500mg (45mg/kg) PO Q12
| |
| | |
| ''OR''
| |
| | |
| Cefdinir 600mg (14mg/kg) PO Daily
| |
| | |
| |-
| |
| | Otitis externa<br/>
| |
| |
| |
| Ciprodex 3gtt Q12
| |
| | |
| ''OR''
| |
| | |
| Polysporin otic 5gtt Q6
| |
| | |
| |-
| |
| | Pharyngitis<br/>
| |
| |
| |
| Bicillin 1.2 million units (25k/kg) IM
| |
| | |
| ''OR''
| |
| | |
| Azithromycin 500mg (12mg/kg) PO Daily
| |
| | |
| |-
| |
| | Corneal abrasion<br/>
| |
| |
| |
| Erythromycin ophthalmic Q6
| |
| | |
| ''OR''
| |
| | |
| Levofloxacin 0.5% 2gtt Q2 ''if patient is a contact user''
| |
| | |
| |-
| |
| | Orbital cellulitis<br/>
| |
| | Vancomycin 1g (15mg/kg) IV Q12<br/>
| |
| |-
| |
| | Appendicitis
| |
| |
| |
| Zosyn 4.5g (100 mg/kg) IV Q6
| |
| | |
| ''OR''
| |
| | |
| Flagyl 500mg (7.5mg/kg) IV Q6
| |
| | |
| ''PLUS''
| |
| | |
| Ciprofloxacin 400mg IV Q12
| |
| | |
| |-
| |
| | Cholecystitis<br/>
| |
| |
| |
| Augmentin 3g IV Q6
| |
| | |
| ''OR''
| |
| | |
| Imipenem/Cilastin 500mg IV Q6
| |
| | |
| |-
| |
| | Diverticulitis
| |
| |
| |
| Flagyl 500mg PO Q6
| |
| | |
| ''PLUS''
| |
| | |
| Ciprofloxacin 750mg PO Q12
| |
| | |
| |-
| |
| | Infectious Diarrhea
| |
| |
| |
| Empiric: Cipro 500mg PO Q12 x3d
| |
| | |
| Giardia: Flagyl 500mg PO Q8 x5d
| |
| | |
| C. diff: Flagyl 500mg PO Q8 x14d
| |
| | |
| |-
| |
| | Epididymitis
| |
| |
| |
| Age <35 (gonorrhea suspected):
| |
| | |
| Doxycycline 100mg PO Q12 x14d
| |
| | |
| ''PLUS''
| |
| | |
| Cefixime 400mg PO once
| |
| | |
| Age >35 (gonorrhea not suspected):
| |
| | |
| Ciprofloxacin 500mg PO Q12 x14d
| |
| | |
| |-
| |
| | Cervicitis/Urethritis
| |
| |
| |
| Cefixime 400mg PO once
| |
| | |
| ''OR''
| |
| | |
| Azithromycin 1g PO once
| |
| | |
| ''ADD''
| |
| | |
| Flagyl 2g PO once ''if concern for trichomoniasis''
| |
| | |
| |-
| |
| | PID<br/>
| |
| |
| |
| Ceftriaxone 250mg 1M once
| |
| | |
| ''PLUS''
| |
| | |
| Doxycycline 100 mg PO Q12 x14d
| |
| | |
| |-
| |
| | UTI<br/>
| |
| |
| |
| Macrobid 100mg PO BID x7d
| |
| | |
| ''OR''
| |
| | |
| Bactrim DS PO Q12 x3d
| |
| | |
| ''OR''
| |
| | |
| Keflex 500mg PO Q6 x7d
| |
| | |
| |-
| |
| | Pneumonia<br/>
| |
| |
| |
| Outpatient:
| |
| | |
| Azithromycin 500mg PO, 250mg PO x3d
| |
| | |
| ''OR''
| |
| | |
| Doxycycline 100mg PO Q12 x7d
| |
| | |
| Inpatient, Community Acquired
| |
| | |
| Ceftriaxone 1g IV
| |
| | |
| ''PLUS''
| |
| | |
| Azithromycin 500mg IV
| |
| | |
| Inpatient, Health Care Acquired
| |
| | |
| Vancomycin 1g IV ''(MRSA)''
| |
| | |
| ''PLUS''
| |
| | |
| Cefepime 2g IV ''(Pseudomonas)''
| |
| | |
| ''PLUS''
| |
| | |
| Tobramycin 4mg/kg IV ''(Pseudomonas)''
| |
| | |
| |-
| |
| | Cellulitis/Superficial Abscess
| |
| |
| |
| Bactrim DS 2tab PO Q12 x5-10d
| |
| | |
| ''PLUS''
| |
| | |
| Cephalexin 500mg PO Q6 x5-10
| |
| | |
| ''OR''
| |
| | |
| Clindamycin 450mg PO Q8 x5-10d
| |
| | |
| Diabetic with systemic toxicity
| |
| | |
| Vancomycin 1g IV
| |
| | |
| ''PLUS''
| |
| | |
| Unasyn 3g IV
| |
| | |
| ''OR''
| |
| | |
| Zosyn 3.375g IV
| |
| | |
| |-
| |
| | Neutropenic fever<br/>
| |
| |
| |
| Zosyn 4.5g IV
| |
| | |
| ''OR''
| |
| | |
| Meropenem 1g IV
| |
| | |
| ''PLUS/MINUS''
| |
| | |
| Gentamicin 2mg/kg IV
| |
| | |
| ''ADD''
| |
| | |
| Vancomycin 1g IV ''for catheter related infection, colonization with MRSA, gram-positive culture unknown susceptibility, suspected sepsis''
| |
| | |
| |}
| |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| == Source<br/> ==
| |
| | |
| University of Cincinnati Department of Emergency Medicine "Handbook of EM Fundamentals"
| |
